Trevena Inc (TRVN) Stock Rating Reaffirmed by Aegis

Trevena Inc (NASDAQ:TRVN)‘s stock had its “buy” rating reissued by stock analysts at Aegis in a note issued to investors on Monday, April 17th. They currently have a $14.00 price objective on the biopharmaceutical company’s stock. Aegis’ target price suggests a potential upside of 353.07% from the company’s current price.

Several other brokerages also recently issued reports on TRVN. Roth Capital set a $9.00 price objective on shares of Trevena and gave the stock a “buy” rating in a research report on Wednesday, February 22nd. Jefferies Group LLC set a $11.00 price target on shares of Trevena and gave the company a “buy” rating in a research report on Wednesday, January 4th. FBR & Co restated an “outperform” rating and set a $8.00 price objective (down from $13.00) on shares of Trevena in a research report on Wednesday, February 22nd. Oppenheimer Holdings Inc. initiated coverage on shares of Trevena in a research note on Thursday, January 5th. They set an “outperform” rating and a $13.00 target price on the stock. Finally, Zacks Investment Research lowered shares of Trevena from a “hold” rating to a “sell” rating in a report on Tuesday, March 14th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have assigned a buy rating to the stock. Trevena currently has a consensus rating of “Buy” and an average price target of $11.73.

Analyst Recommendations for Trevena (NASDAQ:TRVN)

Trevena (NASDAQ:TRVN) traded down 0.32% on Monday, hitting $3.09. 378,285 shares of the stock were exchanged. Trevena has a 52-week low of $3.07 and a 52-week high of $8.03. The firm’s market cap is $180.15 million. The stock’s 50 day moving average price is $3.30 and its 200 day moving average price is $4.96.

Trevena (NASDAQ:TRVN) last posted its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.19. Trevena had a negative return on equity of 66.50% and a negative net margin of 841.00%. Equities research analysts forecast that Trevena will post ($1.51) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Trevena Inc (TRVN) Stock Rating Reaffirmed by Aegis” was first reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://www.com-unik.info/2017/05/20/trevena-inc-trvn-receives-buy-rating-from-aegis-updated-updated-updated.html.

Institutional investors have recently added to or reduced their stakes in the stock. Northpointe Capital LLC raised its position in Trevena by 170.0% in the first quarter. Northpointe Capital LLC now owns 1,163,184 shares of the biopharmaceutical company’s stock valued at $4,269,000 after buying an additional 732,365 shares in the last quarter. Baker BROS. Advisors LP acquired a new position in Trevena during the third quarter valued at approximately $3,038,000. Paulson & CO. Inc. purchased a new stake in shares of Trevena during the first quarter worth about $1,496,000. Palo Alto Investors LLC purchased a new stake in shares of Trevena during the first quarter worth about $1,253,000. Finally, FMR LLC raised its stake in shares of Trevena by 4.5% in the first quarter. FMR LLC now owns 7,037,804 shares of the biopharmaceutical company’s stock worth $25,828,000 after buying an additional 304,256 shares during the last quarter. 69.28% of the stock is currently owned by institutional investors.

About Trevena

Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.

12 Month Chart for NASDAQ:TRVN

What are top analysts saying about Trevena Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Trevena Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit